Gencurix Inc. Logo

Gencurix Inc.

Develops molecular diagnostic tests for cancer detection, prognosis, and treatment selection.

229000 | KO

Overview

Corporate Details

ISIN(s):
KR7229000005
LEI:
Country:
South Korea
Address:
서울특별시 구로구 디지털로 243 지하이시티 15층, 구로구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Gencurix Inc. is a molecular diagnostics company specializing in the development and commercialization of innovative solutions for oncology. The company leverages core technologies such as liquid biopsy and digital PCR (dPCR) to create precise and reliable tests for cancer detection, prognosis, and treatment selection. Its key products include GenesWell BCT, a multigene test for predicting prognosis in early-stage breast cancer patients, and the GenesWell ddEGFR Mutation Test, a dPCR-based companion diagnostic for targeted anticancer therapies. Gencurix also develops the Droplex platform for early cancer detection by analyzing biomarkers from blood samples. The company aims to advance precision medicine and improve patient outcomes through its portfolio of diagnostic tests and services.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-28 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 9.7 KB
2025-08-28 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 16.6 KB
2025-08-28 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 9.8 KB
2025-08-13 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의 (임시주주총회)
Korean 16.6 KB
2025-08-13 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 56.4 KB
2025-08-13 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 53.0 KB
2025-08-11 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-07-03 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2025-07-03 00:00
Pre-Annual General Meeting Information
주주총회소집결의 (임시주주총회)
Korean 6.7 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 34.4 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]증권발행결과(자율공시)
Korean 9.5 KB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]소액공모공시서류(지분증권)
Korean 1.3 MB
2025-06-30 00:00
Share Issue/Capital Change
[기재정정]소액공모실적보고서
Korean 31.1 KB
2025-06-20 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 6.3 KB
2025-06-20 00:00
Share Issue/Capital Change
소액공모실적보고서
Korean 28.0 KB

Automate Your Workflow. Get a real-time feed of all Gencurix Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Gencurix Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Gencurix Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway
AZT
Arcturus Therapeutics Holdings Inc. Logo
Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.
United States of America
ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP

Talk to a Data Expert

Have a question? We'll get back to you promptly.